Cabergoline-induced manic episode: case report. (June 2016)

• Record Type: Journal Article
• Authors: Yüksel, Rabia Nazik; Elyas Kaya, Zeynep; Dilbaz, Nesrin; Cingi Yirün, Merve
• Is Part Of: Therapeutic advances in psychopharmacology. Volume 6:Number 3(2016:Jun.)
• Page Start: 229
• Page End: 231
• Publication Date: 2016-06
• Subjects: Cabergoline -- Bipolar Disorder -- Mania -- Dopamine agonists -- dostinex -- drug-induced mania -- Affective Disorders; Psychopharmacology -- Periodicals; Psychotherapy -- Periodicals; 615.7805
• DOI: 10.1177/2045125315626345
• Languages: English
• ISSNs: 2045-1253

Abstract

Cabergoline is an orally administered synthetic dopamine agonist that is used for the treatment of hyperprolactinemia, Parkinson's disease and antipsychotic-induced prolactin elevation. One of the main characteristics of cabergoline is its long duration of effect. It is highly effective in suppressing prolactin levels up to 21 days after a single 1 mg oral dose. The prolonged elimination half-life offers an advantage of once-daily dosing, but it might be a handicap in terms of washout of adverse effects such as psychosis. Cabergoline has been associated with adverse reactions consistent with other dopaminergic agonists including cardiovascular, gastrointestinal and neuropsychiatric effects. It is known that dopaminergic treatment is a remarkable risk factor for psychosis. A number of reports implicate dopamine agonists in the development of psychosis, but there is no knowledge in the literature of dopamine agonist-induced mania. In this case, we report the first manic episode occurring after cabergoline use for hyperprolactinemia treatment. In susceptible individuals, cabergoline can cause manic episodes and cabergoline should be used more carefully considering the risk–benefit ratio.